These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 38419149)

  • 1. Basiliximab Induction and Postoperative Steroid-free Immunosuppression With Tacrolimus in Pediatric Liver Transplantation: A Randomized Clinical Trial.
    Dong C; Song Z; Sun C; Wang K; Zhang W; Chen J; Zheng W; Yang Y; Wang Z; Han C; Jiao L; Zhang G; Xie E; Gao W; Shen Z
    Transplantation; 2024 Aug; 108(8):1769-1775. PubMed ID: 38419149
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of basiliximab as initial immunosuppression in liver transplantation: A single center study.
    Hashim M; Alsebaey A; Ragab A; Soliman HE; Waked I
    Ann Hepatol; 2020; 19(5):541-545. PubMed ID: 32768592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of basiliximab with a tacrolimus-based regimen in liver transplant recipients.
    Marino IR; Doria C; Scott VL; Foglieni CS; Lauro A; Piazza T; Cintorino D; Gruttadauria S
    Transplantation; 2004 Sep; 78(6):886-91. PubMed ID: 15385809
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of Antithymocyte Globulin, Basiliximab, and Induction-Free Treatment in Living Donor Kidney Transplant Recipients on Tacrolimus-Based Immunosuppression.
    Sonmez O; Ozcan SG; Karaca C; Atli Z; Dincer MT; Trabulus S; Seyahi N
    Exp Clin Transplant; 2024 Apr; 22(4):270-276. PubMed ID: 38742317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Steroid-avoidance immunosuppression regimen in live-donor renal allotransplant recipients: a prospective, randomized, controlled study.
    Nematalla AH; Bakr MA; Gheith OA; Elagroudy AE; Elshahawy el-M; Aghoneim M
    Exp Clin Transplant; 2007 Dec; 5(2):673-9. PubMed ID: 18194120
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized trial of basiliximab induction versus steroid therapy in pediatric liver allograft recipients under tacrolimus immunosuppression.
    Spada M; Petz W; Bertani A; Riva S; Sonzogni A; Giovannelli M; Torri E; Torre G; Colledan M; Gridelli B
    Am J Transplant; 2006 Aug; 6(8):1913-21. PubMed ID: 16771811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Prospective Randomized, Comparative Trial of High-Dose Mizoribine Versus Mycophenolate Mofetil in Combination With Tacrolimus and Basiliximab for Living Donor Renal Transplant: A Multicenter Trial.
    Ishida H; Takahara S; Amada N; Tomikawa S; Chikaraishi T; Takahashi K; Uchida K; Akiyama T; Tanabe K; Toma H;
    Exp Clin Transplant; 2016 Oct; 14(5):518-525. PubMed ID: 27733107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation.
    Gruttadauria S; Vasta F; Mandalà L; Cintorino D; Piazza T; Spada M; Verzaro R; Gridelli B
    Transplant Proc; 2005; 37(6):2611-3. PubMed ID: 16182762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Usefulness of Tacrolimus without Basiliximab in Well-Matched Living-Donor Renal Transplant Recipients in Korea.
    Baek CH; Kim JH; Yu H; Shin E; Cho H; Kim H; Yang WS; Han DJ; Park SK
    Exp Clin Transplant; 2016 Aug; 14(4):389-93. PubMed ID: 27228054
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of single bolus ATG and Basiliximab as induction therapy in presensitized renal allograft recipients receiving tacrolimus-based immunosuppressive regimen.
    Yang SL; Wang D; Wu WZ; Lin WH; Xu TZ; Cai JQ; Tan JM
    Transpl Immunol; 2008 Jan; 18(3):281-5. PubMed ID: 18047938
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tacrolimus-based, steroid-free regimens in renal transplantation: 3-year follow-up of the ATLAS trial.
    Krämer BK; Klinger M; Vítko Š; Glyda M; Midtvedt K; Stefoni S; Citterio F; Pietruck F; Squifflet JP; Segoloni G; Krüger B; Sperschneider H; Banas B; Bäckman L; Weber M; Carmellini M; Perner F; Claesson K; Marcinkowski W; Ostrowski M; Senatorski G; Nordström J; Salmela K
    Transplantation; 2012 Sep; 94(5):492-8. PubMed ID: 22858806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical outcomes of intestinal transplant recipients receiving maintenance basiliximab, sublingual tacrolimus and prednisone: A case series.
    Di Cocco P; Martinino A; Bencini G; Christensen R; Valdepenas B; Petrochenkov E; Akshelyan S; Almario-Alvarez J; Spaggiari M; Tzvetanov I; Benedetti E
    Hum Immunol; 2024 May; 85(3):110787. PubMed ID: 38480040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunological risk stratification and tailored minimisation of immunosuppression in renal transplant recipients.
    Phanish MK; Hull RP; Andrews PA; Popoola J; Kingdon EJ; MacPhee IAM;
    BMC Nephrol; 2020 Mar; 21(1):92. PubMed ID: 32160893
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months.
    Ramirez CB; Doria C; di Francesco F; Iaria M; Kang Y; Marino IR
    J Surg Res; 2007 Apr; 138(2):198-204. PubMed ID: 17292404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of four different immunosuppression protocols without long-term steroid therapy in kidney recipients monitored by surveillance biopsy: five-year outcomes.
    Anil Kumar MS; Irfan Saeed M; Ranganna K; Malat G; Sustento-Reodica N; Kumar AM; Meyers WC
    Transpl Immunol; 2008 Nov; 20(1-2):32-42. PubMed ID: 18773960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Twenty-four hour steroid avoidance immunosuppressive regimen in liver transplant recipients.
    Ju WQ; Guo ZY; Ling X; He XS; Wu LW; Tai Q; Hu AB; Han M; Zhu XF
    Exp Clin Transplant; 2012 Jun; 10(3):258-62. PubMed ID: 22631063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rabbit-ATG or basiliximab induction for rapid steroid withdrawal after renal transplantation (Harmony): an open-label, multicentre, randomised controlled trial.
    Thomusch O; Wiesener M; Opgenoorth M; Pascher A; Woitas RP; Witzke O; Jaenigen B; Rentsch M; Wolters H; Rath T; Cingöz T; Benck U; Banas B; Hugo C
    Lancet; 2016 Dec; 388(10063):3006-3016. PubMed ID: 27871759
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term results of basiliximab induction immunosuppression in pediatric liver transplant recipients.
    Ganschow R; Grabhorn E; Schulz A; Von Hugo A; Rogiers X; Burdelski M
    Pediatr Transplant; 2005 Dec; 9(6):741-5. PubMed ID: 16269045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Corticosteroid-free immunosuppression with tacrolimus following induction with daclizumab: a large randomized clinical study.
    Boillot O; Mayer DA; Boudjema K; Salizzoni M; Gridelli B; Filipponi F; Trunecka P; Krawczyk M; Clavien PA; Ducerf C; Margarit C; Margreiter R; Pallardo JM; Hoeckerstedt K; Pageaux GP
    Liver Transpl; 2005 Jan; 11(1):61-7. PubMed ID: 15690537
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and cost-effectiveness of newer immunosuppressive regimens in renal transplantation: a systematic review and modelling study.
    Woodroffe R; Yao GL; Meads C; Bayliss S; Ready A; Raftery J; Taylor RS
    Health Technol Assess; 2005 May; 9(21):1-179, iii-iv. PubMed ID: 15899149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.